You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


The Bottom Line: NTRK Updates for Your Practice

  • Authors: Alexander Drilon, MD; Lori Wirth, MD; Theodore Laetsch, MD
  • CME / ABIM MOC Released: 4/1/2022
  • Valid for credit through: 4/1/2023, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists and pathologists.

The goal of this activity is to inform oncologists and other clinicians about the latest data related to NTRK fusion-positive solid tumors and to review practical considerations for incorporating these data into the clinical care of their patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Incidence of NTRK gene fusions across tumor types
    • Data from recent clinical trials evaluating treatment of NTRK fusion-positive tumors


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.



  • Alexander Drilon, MD

    Chief, Early Drug Development Service
    Memorial Sloan Kettering Cancer Center
    New York, New York


    Consultant or advisor for: 14ner Oncology; Amgen; Applied Pharmaceutical Science, Inc.; AstraZeneca; Axis; Bayer; Elevation Oncology, Inc; EMD Serono; Entos; Genentech; Ignyta; Janssen; Lilly; Loxo; Melendi; Merus; Monopteros; MORE Health; Novartis; Nuvalent; Pfizer; Prelude; Repare; Roche; Treeline Biosciences; Tyra Biosciences
    Speaker or member of speakers bureau for: AstraZeneca; Bayer; Chugai; Genentech; Ignyta; Lilly; Loxo; Roche
    Research funding from: Exelixis; Foundation Medicine; GlaxoSmithKline; Pfizer; Pharmamar; Taiho; Teva

  • Lori Wirth, MD

    Associate Professor in Medicine
    Harvard Medical School
    Medical Director of the Center for Head and Neck Cancers
    Massachusetts General Hospital
    Boston, Massachusetts


    Consultant or advisor for: Bayer; Coherus; Eisai; Exelixis; Genentech; Iovance; Lilly; Merck; Morphic; PDS Biotech
    Research funding from: Checkmate Pharmaceuticals; Cue Biopharma; Lilly; Novartis

  • Theodore Laetsch, MD

    Associate Professor, Department of Pediatrics
    Abramson Cancer Center, Perelman School of Medicine
    University of Pennsylvania
    Director, Developmental Therapeutics and Rare Tumor Program
    Division of Oncology, Center for Childhood Cancer Research
    Children’s Hospital of Philadelphia
    Philadelphia, Pennsylvania


    Consultant or advisor for: Bayer; Cellectis; Deciphera; Jumo; MassiveBio; Y-mAbs
    Research funding from: Bayer; Novartis; Pfizer


  • Lisa Cockrell, PhD

    Medical Education Director, Medscape, LLC


    Disclosure: Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


The Bottom Line: NTRK Updates for Your Practice

Authors: Alexander Drilon, MD; Lori Wirth, MD; Theodore Laetsch, MDFaculty and Disclosures

CME / ABIM MOC Released: 4/1/2022

Valid for credit through: 4/1/2023, 11:59 PM EST


Select Any Chapter to Begin

Clinical data of the two approved TRK inhibitors is accumulating across a variety of tumor types.

  • Print